Business
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clini...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n ,\n \n April 29, 2021\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from\n \n June 4\n \n – 8, 2021. Details on the abstract and a corresponding poster presentation are shown below.\n \n \n \n \n \n \n Title:\n \n Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma\n \n \n Presentation Type:\n \n Electronic poster\n \n \n Session Title:\n \n Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary\n \n A\n \n bstract Number:\n \n 4144\n \n \n The abstract will be published on the ASCO Annual Meeting website at\n \n 5:00 p.m. ET\n \n on\n \n May 19, 2021\n \n . The corresponding poster will be made available on the meeting website at\n \n 9:00 a.m. ET\n \n on\n \n June 4, 2021\n \n .\n \n \n \n About Oncolytics Biotech Inc.\n \n \n Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning \"cold\" tumors \"hot\" -- through innate and adaptive immune responses to treat a variety of cancers.\n \n \n Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved i...